Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVWF prophylaxis in severe von Willebrand Disease
NCT03879135Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2019
- Primary completion
- Jan 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 9
01
Overview
Phase 3, open-label trial of von Willebrand factor concentrate in von Willebrand disease (VWD) (2 arms), sponsored by Takeda. Primary endpoint: Spontaneous Annualized Bleeding Rate at 12 months. Started Apr 2019; status: completed.
02
Drugs
von Willebrand factor concentrate
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on NCT03879135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03879135.